Display options
Cite
Braicu EI, Darb-Esfahani S, Schmitt WD, et al. High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget. 2017;8(61):102912-102922doi: 10.18632/oncotarget.22076.
Braicu, E. I., Darb-Esfahani, S., Schmitt, W. D., Koistinen, K. M., Heiskanen, L., Pöhö, P., Budczies, J., Kuhberg, M., Dietel, M., Frezza, C., Denkert, C., Sehouli, J., & Hilvo, M. (2017). High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget, 8(61), 102912-102922. https://doi.org/10.18632/oncotarget.22076
Braicu, Elena Ioana, et al. "High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism." Oncotarget vol. 8,61 (2017): 102912-102922. doi: https://doi.org/10.18632/oncotarget.22076
Braicu EI, Darb-Esfahani S, Schmitt WD, Koistinen KM, Heiskanen L, Pöhö P, Budczies J, Kuhberg M, Dietel M, Frezza C, Denkert C, Sehouli J, Hilvo M. High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget. 2017 Oct 26;8(61):102912-102922. doi: 10.18632/oncotarget.22076. eCollection 2017 Nov 28. PMID: 29262533; PMCID: PMC5732699.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Oct 26;8(61):102912-102922. doi: 10.18632/oncotarget.22076. eCollection 2017 Nov 28.

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism.

Oncotarget

Elena Ioana Braicu, Silvia Darb-Esfahani, Wolfgang D Schmitt, Kaisa M Koistinen, Laura Heiskanen, Päivi Pöhö, Jan Budczies, Marc Kuhberg, Manfred Dietel, Christian Frezza, Carsten Denkert, Jalid Sehouli, Mika Hilvo

Affiliations

  1. Department of Gynecology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
  2. On Behalf of the Tumor Bank Ovarian Cancer Network, Berlin, Germany.
  3. Institute of Pathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Tumor bank Ovarian Cancer Network, Berlin, Germany.
  4. Zora Biosciences Oy, Espoo, Finland.
  5. VTT Technical Research Centre of Finland, Espoo, Finland.
  6. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
  7. MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK.

PMID: 29262533 PMCID: PMC5732699 DOI: 10.18632/oncotarget.22076

Abstract

Ovarian cancer is a very severe type of disease with poor prognosis. Treatment of ovarian cancer is challenging because of the lack of tests for early detection and effective therapeutic targets. Thus, new biomarkers are needed for both diagnostics and better understanding of the cellular processes of the disease. Small molecules, consisting of metabolites or lipids, have shown emerging potential for ovarian cancer diagnostics. Here we performed comprehensive lipidomic profiling of serum and tumor tissue samples from high-grade serous ovarian cancer patients to find lipids that were altered due to cancer and also associated with progression of the disease. Ovarian cancer patients exhibited an overall reduction of most lipid classes in their serum as compared to a control group. Despite the overall reduction, there were also specific lipids showing elevation, and especially alterations in ceramide and triacylglycerol lipid species were dependent on their fatty acyl side chain composition. Several lipids showed progressive alterations in patients with more advanced disease and poorer overall survival, and outperformed CA-125 as prognostic markers. The abundance of many serum lipids correlated with their abundance in tumor tissue samples. Furthermore, we found a negative correlation of serum lipids with 3-hydroxybutyric acid, suggesting an association between decreased lipid levels and fatty acid oxidation. In conclusion, here we present a comprehensive analysis of lipid metabolism alterations in ovarian cancer patients, with clinical implications.

Keywords: biomarker; diagnosis; lipidomics; ovarian cancer; prognosis

Conflict of interest statement

CONFLICTS OF INTEREST M.H., K.M.K. and L.H. are employed by Zora Biosciences Oy, which holds patent disclosures for diagnostic tests of ovarian cancer using small molecules. In addition, Zora Bioscien

References

  1. Clin Cancer Res. 2017 Apr 15;23 (8):2081-2092 - PubMed
  2. Sci Rep. 2015 Nov 17;5:16351 - PubMed
  3. Gynecol Oncol. 2016 Jan;140(1):138-44 - PubMed
  4. J Lipid Res. 2013 Oct;54(10):2898-908 - PubMed
  5. Nat Med. 2011 Oct 30;17(11):1498-503 - PubMed
  6. PLoS One. 2011;6(5):e19963 - PubMed
  7. J Neurooncol. 2005 Feb;71(3):267-9 - PubMed
  8. Bioinformatics. 2005 Oct 15;21(20):3940-1 - PubMed
  9. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  10. Biochim Biophys Acta. 2011 Mar;1811(3):148-52 - PubMed
  11. Int J Cancer. 2012 Nov 1;131(9):2034-43 - PubMed
  12. J Ovarian Res. 2009 Oct 09;2:13 - PubMed
  13. Proteomics. 2005 Nov;5(17):4589-96 - PubMed
  14. N Engl J Med. 2012 Feb 16;366(7):610-8 - PubMed
  15. J Clin Endocrinol Metab. 2014 Jan;99(1):E45-52 - PubMed
  16. Mol Cancer Ther. 2008 Jul;7(7):1993-2002 - PubMed
  17. Eur J Gynaecol Oncol. 2008;29(2):158-61 - PubMed
  18. Int J Cancer. 2015 Feb 1;136(3):516-26 - PubMed
  19. Cell Metab. 2013 Aug 6;18(2):153-61 - PubMed
  20. Int J Cancer. 2005 Feb 20;113(5):782-8 - PubMed
  21. Eur Heart J. 2016 Jul 1;37(25):1967-76 - PubMed
  22. BMC Med. 2014 Mar 25;12:53 - PubMed
  23. Cancer Discov. 2012 May;2(5):401-4 - PubMed
  24. Cancer Invest. 2014 Mar;32(3):71-80 - PubMed
  25. Cancer Res. 2016 Feb 15;76(4):796-804 - PubMed
  26. J Biol Chem. 1957 May;226(1):497-509 - PubMed
  27. Endocr Relat Cancer. 2012 Apr 10;19(2):197-208 - PubMed
  28. Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1185-91 - PubMed

Publication Types

Grant support